Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1625 1629
This examiner grants 73% of resolved cases
Timothy R. Rozof is an examiner in Art Unit 1625 of Tech Center 1600. The examiner has 972 resolved cases and an allowance rate of 72.7 percent. This high volume of cases and relatively high allowance rate suggest a consistent and predictable examination style that is generally favorable to applicants. The 972 resolved cases represent a vast amount of experience, indicating that the examiner is well-versed in the technical and legal aspects of the applications they review.
The interview lift is 23.6 percent, indicating that interviews are a highly effective strategy for overcoming rejections. Applicants are encouraged to utilize interviews to clarify technical details and negotiate claim scope, as the 23.6 percent lift shows a significant improvement in outcomes. This suggests that the examiner is open to the collaborative problem-solving that occurs during an interview. Practitioners can use this data to justify the time and expense of scheduling a formal meeting with the examiner to advance prosecution.
The median days to allowance is 737. This is a relatively efficient timeline, suggesting that the examiner processes applications quickly, leading to faster grants for successful applicants. The 737-day median is an excellent benchmark for applicants who prioritize speed in their patent strategy. It allows for a more rapid transition from the application phase to the enforcement or licensing of granted patent rights, providing a significant advantage in fast-moving technology markets.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18885092 | COMPOUND AND LIPID COMPOSITION | Non-Final OA | FUJIFILM Corporation |
| 18815847 | COMPOSITION FOR LIVING BODY | Non-Final OA | FUJIFILM Corporation |
| 17926424 | A COMPOSITION FOR IMPROVING QOL OF A 40-YEAR-OLD OR OLDER POSTMENOPAUSAL WOMAN WITHOUT MENOPAUSAL DISORDER | Non-Final OA | DAICEL CORPORATION |
| 18886532 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18837494 | INSECT, ACARINA AND NEMATODE PEST CONTROL | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18689708 | SUBSTITUTED 2,3-DIHYDRO[1,3]THIAZOLO[4,5-B]PYRIDINES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 18447057 | METHOD AGAINST SNAKE ENVENOMATION | Final Rejection | National Tsing Hua University |
| 18266917 | USE OF MGLUR5 ANTAGONISTS FOR TREATING GAMBLING DISORDER | Final Rejection | Yale University |
| 18837956 | METHODS OF TREATING PROSTATE CANCER | Non-Final OA | AstraZeneca AB |
| 18649114 | COMPOUNDS AND USES THEREOF | Final Rejection | JANSSEN PHARMACEUTICA NV |
| 18649184 | COMPOUNDS AND USES THEREOF | Final Rejection | JANSSEN PHARMACEUTICA NV |
| 18633760 | METHODS FOR REDUCING ISCHEMIA-REPERFUSION INJURIES | Non-Final OA | Duke University |
| 18256747 | COMPOUNDS FOR TREATING EYE DISEASES AND DISORDERS | Final Rejection | Tel Hashomer Medical Research Infrastructure and Services Ltd. |
| 18016625 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | Final Rejection | SANOFI PASTEUR |
| 17951342 | ALDOSE REDUCTASE INHIBITORS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME, ACUTE LUNG INFLAMMATION/INJURY, CARDIAC INJURY AND ANTI-VIRAL THERAPY | Non-Final OA | Applied Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy